Evidence map›Paper›PMID 42395839›Full record

ArticleEndocrine oncology (Bristol, England)2026

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Mathew Gorman, Nawaid Usmani, Michael N Pollak, Sunita Ghosh, Arun Elangovan, Julian Kim, John Thoms, Myriam Bouchard, Michael Peacock, Ye Wang and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Mathew GormanUniversity of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0009-0001-8522-5908
Nawaid UsmaniUniversity of Alberta, Edmonton, Alberta, Canada.
Michael N PollakDepartments of Medicine and Oncology, McGill University, Montreal, Quebec, Canada.
Sunita GhoshUniversity of Alberta, Edmonton, Alberta, Canada.
Arun ElangovanSaskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada.
Julian KimDepartment of Radiation Oncology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
John ThomsDr H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada.
Myriam BouchardCentre Intégré Universitaire de Santé et de Services Sociaux de L' Estrie-Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.
Michael PeacockBC Cancer - Vancouver Center, Vancouver, British Columbia, Canada.
Ye WangLady Davis Institute for Medical Research, Jewish General Hospital and McGill University, Montreal, Quebec, Canada.
Neil E FleshnerUniversity of Toronto, Toronto, Ontario, Canada.
Holly CampbellDalhousie University, Halifax, Nova Scotia, Canada.
Eric VigneaultCentre de Recherche CHU de Québec Université Laval, Québec City, Quebec, Canada.
Francois VincentCentre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières, Quebec, Canada.
Alan SoBC Cancer - Vancouver Center, Vancouver, British Columbia, Canada.
Fabio L CuryMcGill University Health Centre, Montreal, Quebec, Canada.
Harvey C QuonDivision of Radiation Oncology, Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Ryan G CarlsonShirley and Jim Fielding Northeast Cancer Centre, Sudbury, Ontario, Canada.
Carole LambertCentre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Laurence KlotzSunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Kim ChiBC Cancer - Vancouver Center, Vancouver, British Columbia, Canada.
Michael BrundageKingston Regional Cancer Centre, Kingston, Ontario, Canada.
Kerry S CourneyaUniversity of Alberta, Edmonton, Alberta, Canada.
Bernhard J EiglBC Cancer - Vancouver Center, Vancouver, British Columbia, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen deprivation therapy (ADT) is regularly used to treat locally advanced and metastatic prostate cancer (PCa) with toxicities, including metabolic syndrome (MS) and associated adverse hormonal changes. This study evaluated whether metformin mitigates changes in laboratory biomarkers associated with MS and type II diabetes mellitus (T2DM) in PCa patients receiving ADT. PRIME is a phase III double-blind, randomized controlled trial in which 166 normoglycemic patients with PCa receiving ADT were randomized to receive metformin or placebo. For this study, 47 patients from the metformin arm and 32 patients from the placebo arm underwent serum collection and analysis of the following analytes at baseline, 9, and 12 months: IGF-1, IGFBP1, IGFBP2, IGFBP3, IGFBP7, leptin, adiponectin, GDF15, insulin, C-peptide, GIP, GLP-1, and IL-6. Independent

Indexed as

ADTandrogen deprivation therapyhormone changesmetforminPRIMEprostate cancer

Identifiers

PMID42395839
PMCPMC13326723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.